Ryoncil: ODAC/FDA Meeting Discussion, page-793

Halabi throws a curve ball: Suggests correlation too small, "only .38". "I'm still struggling on the whole issue of in vivo versus in vitro."

SI responds: In vitro "It shows a strong correlation, as you have noted."
In vivo: "You are correct, the in vivo correlation is not as strong" .. suggests largely used as a qualitative characteristic

Halabi: it looks like a high MDS does not reflect the benefit here. (*throws curveball*

Si Responds: I think you misinterpret the slide. (*hits it out of the park*)
"In the three on the left, they represent the outcomes of (indiscernible) populations of patients treated with best available therapy today.
*SI goes on to explain how he's saving lives and the correct interpretation of the slide.*

Summarised: "We shift survival code of the patient of what would accepted to be 20 to 40% survival to 60% in six months."

Halabi still not happy: "sample size still really small, follow up, you needed longer follow up"
Halabi seems highly skeptical.